Navigation Links
Enobia Pharma Raises $40.1 Million Series B Financing
Date:9/11/2007

MONTREAL and QUEBEC, Sept. 11 /PRNewswire/ -- Enobia Pharma Inc, announced today that it raised $Cdn 40.1 Million in a Series B multi-tranche financing. The proceeds will be used primarily to fund the Company's novel hypophosphatasia drug development program through Phase 2 clinical trials. There is no known cure for hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.

The financing was co-led by new investors OrbiMed Advisors LLC ("OrbiMed") of New York and CTI Life Sciences Fund of Montreal ("CTI"). The Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000, current investors in the Company, also participated in the round.

Robert Heft, PhD, President and CEO of Enobia said, "With no drug therapy available, hypophosphatasia patients and their families experience prolonged and significant suffering. We are pleased that we were able to attract such world class investors to our company at this important time in our development. We are confident that with their support, we will build on our promising preclinical results to advance the clinical development program of an enzyme replacement therapy for hypophosphatasia."

Jonathan Silverstein, General Partner of OrbiMed said, "We are delighted to be associated with this impressive team working on such a debilitating disease for which there is no cure."

Richard Meadows, Managing Partner of CTI said, "This represents an example of the type of high quality investment opportunity that exists in Quebec and that is capable of attracting the attention and significant investment from our U.S. VC colleagues."

Both Mr. Silverstein and Mr. Meadows will join the newly constituted Board, which also includes: Robert Heft, who previously served on the Board; Fredric Price, also a former Board member, and an investor in this Series B financing who was previously Chairman & CEO of BioMarin Pharmaceutical and Thomas Schuetz, MD, PhD, wh
'/>"/>

SOURCE Enobia Pharma Inc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... news release is available in German . ... too well: with the naked eye, you can see which ... in the blur of branches through the telephoto lens for ... for researchers who are looking to study proteins, the active ... ETH Zurich,s Institute for Molecular Systems Biology, and her colleagues ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ has ... predict the adverse and therapeutic effects of a drug. ... Biology at the Genomics Laboratory, Covance, will discuss the ... when used as part of the QC process. Additionally, ... to identify key clinical targets even in complex data ...
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ultra-low ... USA, won the Outstanding New Product Award presented on ... and Environmental Repositories (ISBER) at their annual meeting in ... recognizes the company’s development and introduction of the world’s ... was presented to Global Cooling’s CEO Neill Lane by ...
Breaking Biology Technology:Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... Inc. has been named "System Integrator of the ... the worldwide competition recognizes the system integration company ... and customer satisfaction. A panel of eight industry ... integrators throughout the world. 
 (Photo: ...
... Calif. and AMSTERDAM, Jan. 5, 2012  Agendia, an ... the company has signed a contract with Blue ... The move paves the way for future in-network ... Blue Cross affiliates across the United States. Developed ...
... CMC Biologics, a leading biopharmaceutical contract manufacturing ... US 2,171,034 B1 covering a method for improving ... bioreactors. The invention is designed to optimize production ... process, wherein the bioreactor (fermenter) has an ultrafiltration ...
Cached Biology Technology:Superior Controls of Seabrook, NH Named System Integrator of the Year for 2012 by Control Engineering Magazine 2Agendia Signs Contract with Blue Shield of California 2CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems 2
(Date:5/16/2013)... have shown a gene involved in neurodegenerative disease also ... the circadian clock. , In a study of ... called Ataxin-2, keeps the clock responsible for sleeping and ... rhythm of the fruit fly,s sleep-wake cycle is disturbed, ... the fly. , The discovery is particularly interesting ...
(Date:5/16/2013)... relationship between the heritable risk for schizophrenia and ... is commonly associated with cognitive impairments that may ... IQ may be linked to the risk for ... precede the onset of schizophrenia symptoms. Also, these ... people diagnosed with schizophrenia. , In a remarkable ...
(Date:5/16/2013)... with ,scissor hand-like, claws in fossil records and has ... , The 505 million year old fossil called ... a distant ancestor of lobsters and scorpions, was named ... as Edward Scissorhands - a movie about an artificial ... for hands. , Kooteninchela deppi is ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2Actor Johnny Depp immortalized in ancient fossil find 2
... in diving beetles ( Dytiscidae ), researchers from the ... glimpse into a bizarre and amazing world of sperm ... including joining together into conglomerates that navigate the twisted ... of the evolutionary relationships among diving beetles reveal that ...
... specific parts of the brain activate when people view particular ... turns on when the eyes glance at faces, and another ... a person looks at scenes or buildings. However, it,s been ... a category of memory that allows the brain to temporarily ...
... eliminate malaria worldwide, new strategies are needed to find ... signs of the disease. The prevalence of asymptomatic or ... percent in populations with malaria and these asymptomatic individuals ... in areas where disease transmission has declined. ...
Cached Biology News:A bug's (sex) life: Diving beetles offer unexpected clues about sexual selection 2A bug's (sex) life: Diving beetles offer unexpected clues about sexual selection 3A bug's (sex) life: Diving beetles offer unexpected clues about sexual selection 4Working memory and the brain 2'Test and Treat' model offers new strategy for eliminating malaria 2